Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Inflammation
Filter     Order     Display # 
Date Item Title Hits
10 Mar 2010 Limerick BioPharma Announces Positive Phase 1a Data for LIM-0705 9
08 Mar 2010 Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold 40
04 Mar 2010 CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy 8
03 Mar 2010 Merck Reports Results of Phase III Study of Investigational Oral Allergy Immunotherapy Tablet (AIT) in Patients Ages 5-17 with Grass Pollen Allergy 160
02 Mar 2010 FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients 9
02 Mar 2010 Data from Two Phase III Studies of Merck’s Investigational Asthma Drug Presented at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 10
24 Feb 2010 New Study Demonstrates Effectiveness of Prochymal as a Rescue Therapy for Pediatric Patients with Severe Graft vs. Host Disease 94
22 Feb 2010 CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis 17
18 Feb 2010 Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program 32
17 Feb 2010 Pharming’s C1 Inhibitor Product Potentially Effective In Reducing Complications Following Transplantation 18
16 Feb 2010 AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA) 17
12 Feb 2010 Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine 17
11 Feb 2010 PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA 26
10 Feb 2010 Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma 30
09 Feb 2010 Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disorders 12
08 Feb 2010 Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions 18
08 Feb 2010 NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults 20
08 Feb 2010 Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors 115
02 Feb 2010 Compugen Discovers Novel Protein for Treatment of Autoimmune Diseases 20
02 Feb 2010 FDA Accepts Javelin Pharmaceuticals' Dyloject(TM) New Drug Application for Formal Review 54
28 Jan 2010 Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indications 22
28 Jan 2010 ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases 86
27 Jan 2010 Lipid Therapeutics announces start of Phase IIb clinical trial 38
22 Jan 2010 NicOx announces EMEA validation of naproxcinod MAA submission 38
21 Jan 2010 SKYEPHARMA PLC - Flutiform U.S. NDA Update 83
20 Jan 2010 Fully Human Monoclonal Anti-TNF-alpha Antibody HUMIRA Receives Approval as Japan's First Biological Agent for Psoriasis 44
19 Jan 2010 Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite and Cat Allergies 25
19 Jan 2010 MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis 30
19 Jan 2010 Biotie reports positive top-line data from clinical study with VAP-1 antibody in rheumatoid arthritis patients - BTT-1023 is well tolerated and shows signals of therapeutic activity 23
19 Jan 2010 Enrollment Open for Clinical Trial of Cytolin, a Novel Immune Therapy from CytoDyn for Treating Early HIV Infection 27
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1255

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics